IL6 and acute respiratory distress syndrome: A prospective study assessing interleukin (IL)-6 levels with or without CytoSorb therapy in acute respiratory distress syndrome (ARDS) patients found decreased IL-6 levels, but no survival benefit in the CytoSorb group [27].